



FOR PROVIDERS.
BY PROVIDERS.

Avoiding Pitfalls and 483s in Medical Gas Transfilling

Presented by: Randy Hughes, RRT

What is transfilling?

- Transferring a gas, either in a liquid or gaseous state, from a larger container into smaller containers (i.e., high-pressure cylinders or cryogenic vessels)
 - Examples
 - Gas to Gas (Cascading)
 - Liquid to Gas
 - Stand tank to Cylinders
 - Large Cryogenic Vessel (LCV) to cylinders
 - Liquid to Liquid
 - Stand tank or LCV to “smaller’ vessel”
 - Vehicle Mounted Vessel (VMV)
 - Cryogenic Home Vessel (CHV)
- Today’s focus is mostly on cylinder filling

Significance of Transfilling

- Manufacturing of a “drug”
 - Manufacturing must conform with Federal Law – Code of Federal Regulations (CFR Title 21 United States Code)
 - Part of which is commonly known as Food, Drug and Cosmetic act
 - Referred to at the Current Good Manufacturing Practices (cGMP’s).
 - Enforced by Food and Drug Administration (FDA)
 - Noncompliance can result in:
 - Product quarantine
 - Product seizure
 - Operation shut-down
 - Civil and Criminal penalties

What is a 483?

- An FDA form 483 is used by investigators to document findings found during an investigation that may constitute violations of the Food Drug and Cosmetic Act.
- The 483 notifies a company of the findings for which they must devise and implement a corrective action plan.

Common FDA Deficiencies (483s)

- There are many FDA deficiencies (483's) that can be noted during the transfilling process, we will discuss the most common.
 - Adulterated Product
 - Any drug which is not recognized in an official compendium* is adulterated if its strength differs from, or its purity or quality falls below that which it purports or is represented to possess, when tested by scientifically sound methods.
 - Any purported drug that was produced in a manner that calls into question the strength, purity or quality
 - Made from “bad product”
 - Made in a facility or manner that could result in improper strength, purity or quality

*Compendium – “a collection of concise but detailed information about a particular subject, especially in a book or other publication.” In this case the publication is the United States Pharmacopeia (USP).

Common FDA Deficiencies (483s)

- Mis-Branded product
 - “Labeling” is false or misleading in any particular manner
 - Place of business (manufacturer, packer or distributor) is not clearly obvious
 - Ordinary person cannot understand name of the drug or the product/content of the vessel

Common FDA Deficiencies (483s)

- Facility
 - Cleanliness
 - Condition of fill system
 - Lighting
 - Storage designation
 - Security

Common FDA Deficiencies (483s)

- Analyzer calibration
 - Calibration Gases
 - Certificates Of Analysis (COA)
 - Following manufacturer guidelines
 - Battery
 - Flow/pressure
 - Stability
 - Evidence of up-to-date Preventive Maintenance (PM)

Common FDA Deficiencies (483s)

- Incoming product documentation
 - Certificate of analysis (COA)
 - Testing?
- Label control process
 - Ordering
 - Count
 - Security
- Staff training
 - cGMP
 - “Ongoing”

Common FDA Deficiencies (483s)

- Filling process
 - Staff knowledge of fill system components
 - PPE
 - USP label
 - Zero verification of vacuum pump
 - Nitrogen (N₂) re-pressurization
 - Heat of compression
 - Temperature/Pressure conversion chart

Common FDA Deficiencies (483s)

- Batch Production Records
 - Errors and error correction
 - Filler signature
 - Quality Control Unit (QCU) review of each batch
 - Check marks vs actual number (digit)

Common FDA Deficiencies (483s)

- Post fill
 - Leak test
 - Hold for release
 - QCU review

Minimizing Exposure

- Random unannounced audits of actual fill
 - Robust record review audits
 - Analyzer calibration logs
 - Label control logs
 - Batch production records
 - PM and testing records
 - Include as part of Performance Improvement activities
 - Train, Train again, verify and re-train as necessary



FOR PROVIDERS.
BY PROVIDERS.

Questions?